吡格列酮与二甲双胍通过激活PPAR信号通路减轻血友病性关节病进展
本研究以血友病A大鼠为模型,通过RNA测序发现PPAR信号通路激活可能是血友病性关节病的保护因素,并测试了吡格列酮、二甲双胍及联合方案。三种方案均不能改善自发性出血表型,但可有效预防和减轻早期血友病性关节病,且耐受性良好。
要点
- PPAR信号通路激活可能对血友病性关节病具有保护作用。
- 吡格列酮30 mg/kg/d、二甲双胍150 mg/kg/d及联合方案可预防早期关节病。
- 上述治疗不能缓解血友病A大鼠的自发性出血表型。
核心结论
- 激活PPAR信号通路的治疗有潜力预防和管理早期血友病性关节病,或可试用于患者以降低残疾风险。
研究设计与样本
- 采用血友病A大鼠模型,以针穿刺法诱导关节出血模拟血友病患者关节病。
- 通过RNA测序鉴定与关节病组织损伤相关的转录组改变,并测试药物方案。
- 设计三种方案:吡格列酮30 mg/kg/d、二甲双胍150 mg/kg/d、吡格列酮15 mg/kg/d联合二甲双胍150 mg/kg/d。
- 治疗持续3天,分别在出血诱导前3天或出血诱导后立即开始。
- 通过关节肿胀测量和组织病理学检查评估结局。
主要发现
- RNA测序发现PPAR信号通路激活可能是血友病性关节病的保护因素,可能由PPARγ上调及随后抑制炎症通路介导。
- 三种治疗方案均未减轻血友病A大鼠的自发性出血表型。
- 三种治疗方案均能有效预防和减轻早期血友病性关节病。
- 这些治疗在临床前研究中耐受性良好。
临床怎么用
- PPAR信号通路激活治疗可能用于预防和管理早期血友病性关节病。
- 该策略或可试用于患者以降低残疾风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemophilic arthropathy poses major clinical challenges. Joint bleeding leads to iron deposition, inflammation, and synovial hyperplasia, causing joint damage. Nevertheless, the mechanisms involved in the disease progression needs deeper exploration so that effective intervention can be proposed. OBJECTIVES: We aimed at investigating the relevant signaling pathways in hemophilic arthropathy pathogenesis and evaluate potential therapeutic measures through targeted regulatory approach. METHODS: Hemophilia (H)A rats were used as the experimental model. To mimic arthropathy caused by joint bleeding in hemophilic patients, we induced joint hemorrhage with a needle puncture method. RNA-sequencing was carried out to identify transcriptomic alterations associated with tissue damage of arthropathy, and drug treatment protocols were tested in these HA rats. Outcomes were assessed via joint swelling measurements and histopathological examination. RESULTS: We identified, through RNA-sequencing, the activation of peroxisome proliferator-activated receptors (PPAR) signaling pathway as a possible protective factor in hemophilic arthropathy, potentially mediated by PPARγ upregulation and subsequent suppression of inflammatory pathways. Three treatment protocols were designed, namely, pioglitazone (30 mg/kg/d), metformin (150 mg/kg/d), and combination treatment of pioglitazone (15 mg/kg/d) and metformin (150 mg/kg/d). These treatments were administered for 3 days, starting either 3 days before or immediately after hemorrhage induction. Although none of these treatments alleviated spontaneous bleeding phenotypes in HA rats, they were found to effectively prevent and attenuate early-stage hemophilic arthropathy. These treatments were well-tolerated in preclinical studies. CONCLUSION: The treatment for PPAR signaling activation shows potential for preventing and managing early hemophilic arthropathy and may be tried in patients to reduce disability risk.
引用
- Zhou Y, Shen Y, Yao SX, et al. Pioglitazone and metformin attenuate hemophilic arthropathy progression via peroxisome proliferator-activated receptor signaling pathway activation. J Thromb Haemost. 2026. PMID: 42107709. doi:10.1016/j.jtha.2026.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。